Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Performance-Enhancing Drugs at Work: An Ethics Poll
- Performance-Enhancing Drugs at Work: An Ethics PollNot an either/orThe use of synthetic drugs to enhance performance is an issue to me, not so much because it helps an individual perform better, but because of the long-term effects on the brain and body. The extended use of steroids has been proven...
- Discussion threads 2008-05-13
Additional Resources
- Shire Pharmaceuticals Group PLC - ADDERALL XR - Paragraph IV Notice Update.
- Embargoed until 7 am EST 12 noon BST ADDERALL XRA' - Paragraph IV Notice Update Basingstoke, UK and Philadelphia, US - April 11, 2005 - Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced on February 23rd, 2005...
- Research articles 2005-04-11
- Shire Pharmaceuticals Group PLC - ADDERALL XR(R) - Shire submits Citizen Petition to FDA.
- ADDERALL XRA' - Shire submits Citizen Petition on efficacy and safety concerns with the FDA Basingstoke, UK and Philadelphia, US October 13, 2005 - Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that on October 12, 2 ADDERALL XRA' -...
- Research articles 2005-10-13
- Shire sues Teva over copycat Adderall XR.
- Shire Pharmaceuticals is suing Israeli generics company Teva Pharmaceuticals. It claims Teva has infringed patents protecting its attention deficit hyperactivity disorder drug Adderall XR, and has a filed a lawsuit in Pennsylvania. Teva is poised to Shire Pharmaceuticals is suing Israeli generics company Teva ...
- Research articles 2006-03-10
- ADDERALL XR(R) - Paragraph IV notice received.
- Immediate release ADDERALL XRA' - Paragraph IV notice received Basingstoke, UK and Philadelphia, US - 2 December 2004 - Shire Pharmaceuticals Group plc (LSE: SHP,...
- Research articles 2004-12-02
- ADDERALL XR(R) - Paragraph IV Notice Received.
- BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, December 2 /PRNewswire/ -- Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it has received a Paragraph IV Notice letter from Colony Pharmaceuticals Inc., advising of the filing of an Abbreviated New Drug...
- Research articles 2004-12-02
- IMPAX Announces Shire's Lawsuit Related to Generic Version of Adderall XR
- HAYWARD, Calif. -- IMPAX Laboratories, Inc. (OTC:IPXL) today announced that an affiliate of Britain's Shire Pharmaceuticals Group Plc ("Shire") has filed a complaint against the Company in the United States District Court for the Southern District of New York, alleging patent infringement related to a third patent for Adderall XR....
- Research articles 2005-10-24
- ADDERALL XR(R) - Paragraph IV Notice Received.
- BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, October 3 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it has received a Paragraph IV notice letter from Andrx Pharmaceuticals, L.L.C. Andrx advising...
- Research articles 2006-10-03
- Shire Pharmaceuticals Group PLC - ADDERALL XR (R) - Impax Files Suit against Shire.
- For immediate release ADDERALL XRA'- Impax Files Suit against Shire for Invalidity and Non-infringement of U.S. Patent No. 6,913,768 ...
- Research articles 2005-11-11
- Shire Q2: The Party's Over as Teva's Generics Decimate Adderall
- For months, Shire has been trying to defy gravity by jacking up the price of Adderall XR in order to encourage users to switch to its cheaper, new ADHD drug, Vyvanse. This quarter it came down to earth as sales collapsed in the face of generic competition. by Jim Edwards
- Blog posts 2009-08-05
- The Pfizer-Shire Deal Worst-Case Scenario
- Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...
- Blog posts 2009-01-07
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- Shire's Big Gamble on ADHD Drug Vyvanse
- One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...
- Blog posts 2008-09-04
- Shire Q4: Bad News Lurks Behind the Good News
- Shire revealed its Q4 2008 results today in a press release that uses a cunning new transparency trick: It gives so much information, in so many different forms, that it's difficult to figure out quickly what exactly is going on at this company. Here's Shire's official take...
- Blog posts 2009-02-19
- Shire pharma faces early challenge.
- Shire Pharmaceuticals' attention-deficit drug Adderall XR could face generic competition as early as 2006, despite its approval this week by the US Food and Drug Administration FDA for adult use. Shire Pharmaceuticals' attention-deficit drug Adderall XR could face generic competition as early as 2006,...
- Research articles 2004-08-20
- Barr Pharmaceuticals Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. Our first question comes from the line of Randall Stanicky from Goldman Sachs. Please go ahead. Randall Stanicky - Goldman Sachs Hey guys, thanks for the question. And I guess this is congratulation on what could be the last Barr call here. I guess just, could...
- Earnings calls 2008-11-06
- View From The City: Brokers' Reports
- SHIRE PHARMACEUTICALS This is Robin Gilbert of Numis on Shire Pharmaceuticals, the FTSE 100 drug-maker. "The company has now obtained US approval for its Adderall product for attention deficit disorder to be prescribed to adults, being only approved for use in children until now. This is a...
- Research articles 2004-08-14
- The Teva-Shire Deal Worst-Case Scenario
- The rumors that Teva might attempt to buy Shire are puzzling because such an acquisition would present a huge internal conflict to the combined company: What to do with Shire's Vyvanse and Adderall XR brands, which are in direct competition with Teva's generic Adderall pills? by Jim Edwards
- Blog posts 2009-08-24
- Shire CEO: Government Probes Are Normal
- Another day, another subpoena. And the latest was sent to Shire last month by the US Department of Health and Human Services Office of Inspector General, which is working with the US Attorney in Philadelphia. The focus of their interest is the sales and marketing practices for three ADHD drugs...
- News items 2009-10-30
- Brain Steroids: Ban Or Boost?
- Drugs are bad for productivity, right? Well, maybe not. While you can probably correlate productivity increases with declines in per capita drinking, what about coffee or Diet Coke? These can act as mild stimulants. Then there's full-fledged brain steroids, say, a drug like Provigil, which...
- Blog posts 2008-03-24
- << Previous
- page 1 of 1
- Next >>
Presented by American Express